Q&A: Treatment options expanding for inadequately controlled asthma

Three months after receiving FDA approval as a maintenance treatment for patients aged at least 12 years with asthma, Breztri Aerosphere is commercially available, according to a press release. The Breztri Aerosphere (AstraZeneca) inhaler combines 160 μg budesonide, an inhaled corticosteroid; 18 μg glycopyrrolate, a long-acting muscarinic antagonist; and 4.8 μg formoterol fumarate,